Incyte (INCY) PT Raised to $134 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $122.85 +4.47%
Rating Summary:
19 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
19 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Barclays analyst Etzer Darout raised the price target on Incyte (NASDAQ: INCY) to $134.00 (from $117.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Incyte (INCY) PT Raised to $108 at Bernstein SocGen Group
- Incyte to present hematology data across 30+ abstracts at ASH 2026
- CVS Health (CVS) PT Lowered to $103 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
